{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T07:54:35Z","timestamp":1648626875229},"reference-count":9,"publisher":"Medwave Estudios Limitada","issue":"suppl3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medwave"],"DOI":"10.5867\/medwave.2015.6363","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T17:53:59Z","timestamp":1452707639000},"page":"e6363-e6363","source":"Crossref","is-referenced-by-count":0,"title":["Are biologics useful for nail psoriasis?"],"prefix":"10.5867","volume":"15","author":[{"given":"Andrea","family":"Ant\u00fanez-Lay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cabrolier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Andino-Navarrete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3888","published-online":{"date-parts":[[2015,12,31]]},"reference":[{"issue":"7","key":"ref0","first-page":"1452","article-title":"Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013 Jan 31;1:CD007633. | CrossRef | PubMed | Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review.","volume":"33","author":"de Vries","year":"2006","unstructured":"de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, et al. Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013 Jan 31;1:CD007633. | CrossRef | PubMed | Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol. 2006 Jul;33(7):1452-6. | PubMed |","journal-title":"J Rheumatol","ISSN":"http:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.","volume":"58","author":"Rich","year":"2008","unstructured":"Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008 Feb;58(2):224-31. | PubMed |","journal-title":"J Am Acad Dermatol","ISSN":"http:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"issue":"3","key":"ref2","first-page":"242","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr;60(4):976-86. | CrossRef | PubMed | Igarashi A, Kato T, Kato M, Song M, Nakagawa H; Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial.","volume":"39","author":"Kavanaugh","year":"2012","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr;60(4):976-86. | CrossRef | PubMed | Igarashi A, Kato T, Kato M, Song M, Nakagawa H; Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial. J Dermatol. 2012 Mar;39(3):242-52. | CrossRef | PubMed |","journal-title":"J Dermatol","ISSN":"http:\/\/id.crossref.org\/issn\/0385-2407","issn-type":"print"},{"issue":"9494","key":"ref3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.","volume":"366","author":"Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005 Oct 15-21;366(9494):1367-74. | PubMed |","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"2","key":"ref4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000317775","article-title":"Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.","volume":"221","author":"Reich","year":"2010","unstructured":"Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology. 2010;221(2):172-8. | CrossRef | PubMed |","journal-title":"Dermatology","ISSN":"http:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"ref5","first-page":"4","article-title":"Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy (Abstract O-10). The 85th BAD Annual Meeting 5-8th July 2005, Glasgow, UK.","volume":"153","author":"Reich","year":"2005","unstructured":"Reich R, Nestle F, Ortonne JP, Papp K, Evans R, Guzzo C, et al. Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy (Abstract O-10). The 85th BAD Annual Meeting 5-8th July 2005, Glasgow, UK. British journal of dermatology. 2005;153(Suppl 1):4. | Link |","journal-title":"Br J Dermatol","ISSN":"http:\/\/id.crossref.org\/issn\/0007-0963","issn-type":"print"},{"issue":"2","key":"ref6","first-page":"AB178","article-title":"Nail psoriasis improvement is maintained in patients with moderate to severe psoriasis treated with infliximab Abstract P2716. American Academy of Dermatology 65th Annual Meeting February 2-6, 2007.","volume":"56","author":"Rich","year":"2007","unstructured":"Rich P, Guzzo C, Li S, Reich K. Nail psoriasis improvement is maintained in patients with moderate to severe psoriasis treated with infliximab Abstract P2716. American Academy of Dermatology 65th Annual Meeting February 2-6, 2007. J Am Acad Dermatol. 2007;56(2):AB178. | CrossRef |","journal-title":"J Am Acad Dermatol","ISSN":"http:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"issue":"6","key":"ref7","first-page":"1101","article-title":"Significant response of nail psoriasis to infliximab in patients with moderate to severe psoriasis disease. 14th Congress of the European Academy of Dermatology and Venereology, London,UK. Journal of the European Academy of Dermatology and Venereology 2005;19(Suppl 2):171. | Link | Bianchi L, Bergamin A, de Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol. 2005 Apr;52(4):736-7. | PubMed | Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: a small case series.","volume":"52","author":"Rich","year":"2005","unstructured":"Rich P, Scher R, Reich K, Nestle F, Papp K, Evans R, et al. Significant response of nail psoriasis to infliximab in patients with moderate to severe psoriasis disease. 14th Congress of the European Academy of Dermatology and Venereology, London,UK. Journal of the European Academy of Dermatology and Venereology 2005;19(Suppl 2):171. | Link | Bianchi L, Bergamin A, de Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol. 2005 Apr;52(4):736-7. | PubMed | Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol. 2005 Jun;52(6):1101-2. | PubMed |","journal-title":"J Am Acad Dermatol","ISSN":"http:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"issue":"5","key":"ref8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.","volume":"161","author":"Smith","year":"2009","unstructured":"Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009 Nov;161(5):987-1019. | CrossRef | PubMed |","journal-title":"Br J Dermatol","ISSN":"http:\/\/id.crossref.org\/issn\/0007-0963","issn-type":"print"}],"container-title":["Medwave"],"original-title":["\u00bfEs \u00fatil la terapia biol\u00f3gica para la psoriasis ungueal?"],"link":[{"URL":"https:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T15:56:45Z","timestamp":1562860605000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,31]]},"references-count":9,"journal-issue":{"issue":"suppl3","published-online":{"date-parts":[[2015,12,31]]}},"URL":"https:\/\/doi.org\/10.5867\/medwave.2015.6363","relation":{},"ISSN":["0717-6384"],"issn-type":[{"value":"0717-6384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,31]]}}}